Can-Fite BioPharma Ltd. [CANF] stock is up 8.51 while the S&P 500 has fallen -0.67% on Wednesday, 10/14/20. While at the time of this article, CANF ATR is sitting at 0.12. This stock’s volatility for the past week remained at 6.38%, while it was 5.70% for the past 30-day period. CANF has risen $0.16 from the previous closing price of $1.88 on volume of 1.29 million shares.

On 13, October 2020, Can-Fite to Host Conference Call to Update Shareholders on Positive Interim Results of its Phase III Psoriasis Study on October 15, 2020. According to news published on Yahoo Finance, Key Opinion Leader in the Treatment of Psoriasis to Join the Presentation and Q&A.

Analyst Birdseye View:

The most recent analyst activity for Can-Fite BioPharma Ltd. [AMEX:CANF] stock was on October 19, 2016, when it was Resumed with a Buy rating from ROTH Capital. Before that, on August 11, 2017, Maxim Group Recapitulated a Buy rating and elevated its amount target to $7. On August 29, 2016, Rodman & Renshaw Resumed a Buy rating and boosted its price target on this stock to $6. On November 30, 2015, H.C. Wainwright Reiterated a Buy rating and increased its price target from $4 to $6. On March 31, 2015, H.C. Wainwright Reiterated a Buy rating and decreased its price target to $3. On March 30, 2015, ROTH Capital Downgrade a Neutral rating and boosted its amount target on this stock to $2.40. On December 29, 2014, ROTH Capital Reiterated a Buy rating and decreased its target amount on this stock from $28 to $20. H.C. Wainwright elevated its amount target by recapitulating a higher weight for this stock.

In the past 52 weeks of trading, this stock has oscillated between a low of $1.08 and a peak of $4.95. Right now, the middling Wall Street analyst 12-month amount mark is $5.00. At the most recent market close, shares of Can-Fite BioPharma Ltd. [AMEX:CANF] were valued at $2.04.


Can-Fite BioPharma Ltd. [AMEX:CANF] most recently reported quarterly sales of 716.2 million, which represented growth of -47.60%. This publicly-traded organization’s revenue is $905,004 per employee, while its income is -$4,269,818 per employee. Continuing to look at profitability, this corporation’s Return on Assets, Equity, Whole Principal & invested Principal is sitting at -117.89, -477.89, -587.68 and -473.43 respectively.

If looking now at the Principal structure of this organization, it shows its whole liability to the whole Principal at 7.88 and the whole liability to whole assets at 0.92. It shows enduring liability to the whole principal at 4.10 and enduring liability to assets at 0.00 while looking for an extended time period.

Readers are usually of view to make a close observation to the indicators that support and make resistance before moving to any particular stock. As of now, the company’s stock is sitting at 1.88 points at 1st support level, the second support level is making up to 1.72. But as of 1st resistance point, this stock is sitting at 2.15 and at 2.26 for 2nd resistance point.

Can-Fite BioPharma Ltd. [CANF] reported its earnings at -$1.05 per share in the fiscal quarter closing of 6/29/2020. The Analysts for Wall Street were expecting to report its earnings at -$0.3/share signifying the difference of -0.75 and -250.00% surprise value. Comparing the previous quarter ending of 3/30/2020, the stated earnings were -$0.9 calling estimates for -$0.24/share with the difference of -0.66 depicting the surprise of -275.00%.

Important Ratio’s To Watch

Quick ratio, showing Cash ratio at 0.84. Now if looking for a valuation of this stock’s amount to sales ratio it’s 4.44 and it’s amount to book ratio is 14.89.